Relaxant Effects of Sildenafil on the Human Isolated Bladder Neck

Urology

Volumn 73, Issue 2, 2009, Pages 427-430

  Bittencourt, José Augusto F ^a   Tano, Tania ^a   Gajar, Sessin A ^a   Resende, Ângela C ^a   de Lemos Neto, Miguel ^a   Damião, Ronaldo ^a   Criddle, David N ^b   Freitas de Bem, Graziele ^c   Soares de Moura, Roberto ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; POTASSIUM CHLORIDE; SILDENAFIL;

ADULT; AGED; ARTICLE; BLADDER MUSCLE; BLADDER NECK; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DISSECTION; DRUG EFFECT; HISTOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; ISOLATED ORGAN; MALE; PRIORITY JOURNAL; PROSTATECTOMY; SMOOTH MUSCLE RELAXATION;

AGED; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXATION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; URINARY BLADDER;

EID: 58649097674     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.06.060     Document Type: Article

References (26)

1. Reitz A., Muntener M., Kaferkamp A., et al. Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway?. BJU Int 96 (2005) 250-253
2. Carson C.C. Combination of phosphodisterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?. BJU Int 97 (2006) 39-43
3. Chapple C.R. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practicing clinician. BJU Int 94 (2004) 738-744
4. Clifforf G.M., and Farmer R.D. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 38 (2000) 2-19
5. Tinel H., Steite-Ludwig B., Hutter J., et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98 (2006) 1259-1263
6. Simonsen U., Garcia-Sacristan A., and Prieto D. Penile arteries and erection. J Vasc Res 39 (2002) 283-303
7. Ehrén I., Iversen H., Jansson O., et al. Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 44 (1994) 683-687
8. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 151 (1994) 54-61
9. Mulhall J.P., Guhring P., Parker M., et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3 (2006) 662-667
10. Kulinskaya K.S.E., McNicholas T.A., Boustead G.B., et al. Sildenafil influences lower urinary tract symptoms. BJU Int 90 (2002) 836-839
11. Siroky M.B. Lower urinary tract symptoms: shifting our focus from the prostate to the bladder. J Urol 172 (2004) 1237-1238
12. Vanhoutte P.M., and Mombouli J.V. Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis 39 (1996) 229-239
13. Moon A. Influence of nitric oxide signaling pathways on pre-contracted human detrusor smooth muscle in vitro. BJU Int 89 (2002) 942-949
14. Takeda M., Tang R., Shapiro E., et al. Effects of nitric oxide on human and canine prostates. Urology 45 (1995) 440-446
15. Klotz T., Mathers M.J., Bloch W., et al. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 31 (1999) 335-341
16. Montorsi F., Corbin J., and Phillips S. Review of phosphodiesterase in the urogenital system: new directions for therapeutic intervention. J Sex Med 1 (2004) 322-336
17. Truss M.C., Uckert S., Stief C.G., et al. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. Urol Res 24 (1996) 123-128
18. Qiu Y., Kraft P., Craig E.C., et al. Identification and functional study of phosphodiesterases in rat urinary bladder. Urol Res 29 (2001) 388-392
19. Werkström V., Svensson A., Andersson K.E., et al. Phosphodiesterase five in the female pig and human urethra: morphological and functional aspects. BJU Int 98 (2006) 414-423
20. Filippi S., Morelli A., Sandner P., et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148 (2007) 1019-1029
21. Uckert S., Kuthe A., Jonas U., et al. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166 (2001) 2484-2490
22. Gajar A.S., Tano T., Resende A.C., et al. Inhibitory effect of sildenafil on the human isolated seminal vesicle. BJU Int 100 (2007) 1322-1325
23. Lau L.C., and Adaikan P.G. Effect of sildenafil and Rolipram on adrenergic responses in isolated human and monkey corpus cavernosum. Eur Urol 52 (2007) 253-260
24. McVary K.T., Roehrborn C.G., Kaminetsky J.C., et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177 (2007) 1401-1407
25. McVary K.T., Monnig W., Camps J.L., et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177 (2007) 1071-1077
26. Ehrén I., Adolfsson J., and Wiklund N.P. Nitric oxide synthase activity in the human urogenital tract. Urol Res 22 (1994) 287-290